Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial
Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial
Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial
Key points
اہم نکات
मुख्य बातें
- French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy.
- In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals.
- Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile.
- French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy.
- In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals.
- Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile.
- French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy.
- In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals.
- Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile.
French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy. In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals. Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile. The failure also raises questions about sevasemten's ongoing trial in Duchenne muscular dystrophy, a more severe form of the disease.
French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy. In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals. Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile. The failure also raises questions about sevasemten's ongoing trial in Duchenne muscular dystrophy, a more severe form of the disease.
French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy. In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals. Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile. The failure also raises questions about sevasemten's ongoing trial in Duchenne muscular dystrophy, a more severe form of the disease.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।